Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimer’s Disease (R01 - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the “ApoE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/crosstalk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.


  • Letter of Intent Due Date(s): February 26, 2018
  • Application Due Date(s): March 28, 2018

RFA-AG-18-022 Expiration Date March 29, 2018

Agency Website



Amount Description

Application budgets are limited to a maximum of $500,000 per year in direct costs and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years. 

    Funding Type





    Medical - Basic Science
    Medical - Translational

    External Deadline

    March 28, 2018